Companies › VeonGen Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Ophthalmology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VG801 Gene therapy for ABCA4 mutation-associated retinal dystrophy | ABCA4 | Phase 1 | Retinal Dystrophy Due to Biallelic ABCA4 Mutations | Dec 2027 |
| VG901 AAV2-mediated gene therapy delivering functional CNGA1 gene | CNGA1 | Phase 1 | Retinitis Pigmentosa | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06291935 | VG901 | Phase 1 | Retinitis Pigmentosa | Ophthalmology | Apr 2026 |
| NCT07002398 | VG801 | Phase 1 | Retinal Dystrophy Due to Biallelic ABCA4 Mutations | Ophthalmology | Dec 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.